Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and kidney disease as assessed by Steno T1 Risk Engine in adults with type 1 diabetes.
Elisabeth Buur StougaardEllen BurgessDorte VistisenPhillip BanksManon GirardMichael J DaviesFrederik PerssonPublished in: Diabetes, obesity & metabolism (2023)
Keyphrases